Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2879552 in Relapsed/Refractory Small Cell Lung Carcinoma
NCT02034123Phase 1Terminated
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of GSK2879552 in Small Cell Lung Cancer (SCLC) (2 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs, Number of Participants With Dose Limiting Toxicities and 6 more. Started Feb 2014; status: terminated.
02
Drugs
GSK2879552
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT02034123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034123.